Seasonal Influenza Vaccine Effectiveness, 2013-2014
Age | Number | % Total |
---|---|---|
6 months-8 years | 1,125 | 20 |
9-17 years | 625 | 11 |
18-49 years | 2,168 | 39 |
50-64 years | 1,096 | 20 |
65+ years | 623 | 11 |
Gender | Number | % Total |
---|---|---|
Male | 2,367 | 40 |
Female | 3,632 | 60 |
Race | Number | % Total |
---|---|---|
White, non-Hispanic | 4,330 | 78 |
Black, non-Hispanic | 407 | 7 |
Hispanic | 434 | 8 |
Other, non-Hispanic | 398 | 7 |
On This Page
- Patients by Age
- Patients by Gender
- Patients by Race
- Influenza Virus Type And Subtype Among Influenza-Positive Patients
- Influenza vaccine effectiveness for all vaccine types, against influenza A or B viruses
- Influenza vaccine effectiveness for all vaccine types, against influenza A (H1N1) viruses
- Influenza vaccine effectiveness for Live Attenuated Influenza Vaccines in children, against influenza A or B viruses
- Influenza vaccine effectiveness for Inactivated Influenza Vaccine in children, against influenza A or B viruses
Coinfections present include: 5 cases coinfected with Influenza A (H3N2) and Influenza B Yamagata; 1 case coinfected with Influenza A (H3N2) and Influenza B Yamagata (lineage not determined); 1 case coinfected with Influenza A (not subtyped) and Influenza B Yamagata; 3 cases coinfected with Influenza B Yamagata and Influenza B/Victoria
Top of Page Top of Page- Page last reviewed: September 7, 2018
- Page last updated: September 7, 2018
- Content source:
- Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases (NCIRD)
- Page maintained by: Office of the Associate Director for Communication, Digital Media Branch, Division of Public Affairs